Presentations for the September 27, 2019 Joint Meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees
- FDA Presentations
- Neuropsychiatric Events with the use of Montelukast in Pediatric Patients
- Pediatric Utilization Patterns Montelukast, 2014-2018
- Neuropsychiatric Events Associated with Montelukast: Postmarketing Experience
- Neuropsychiatric Adverse Events and Montelukast: Observational Safety Analyses
- FDA Summary and Discussion Topics
- Additional Slides